Although targeting CCND1 gene and protein levels may represent a therapeutic option in HNSCC, this may not be currently feasible, and instead, we focused on targeting their associated kinases, CDKs, as CDK inhibitors are already approved for other indications, thereby enhancing the translational potential of our studies. Here, CCND1 is linked to head and neck squamous cell carcinoma.